This site is not optimized for Internet Explorer 8 (or older).

Please upgrade to a newer version of Internet Explorer or use an alternate browser such as Chrome or Firefox.

Surgical and Transcatheter Management of MR: Competing or Complementary?

Thursday, May 21, 2020

Kaneko T, Tang GHL, Ailawadi G, Reardon MJ. Surgical and Transcatheter Management of MR: Competing or Complementary?. May 2020. doi:10.25373/ctsnet.12320843

Filmed at the 2020 STS Annual Meeting in New Orleans, Louisiana, Tsuyoshi Kaneko of Brigham and Women's Hospital in Boston, Massachusetts, USA, moderates a discussion on surgical and transcatheter management of mitral regurgitation (MR). He is joined by Michael J. Reardon of Houston Methodist Hospital in Texas, USA, Gorav Ailawadi of the University of Virginia, and Gilbert H. L. Tang of Mount Sinai Health System in New York City. They discuss the use of transcatheter vs. surgical therapies to treat MR.They focus both on degenerative and funtional MR, patient selection, and the the future of this field.


Dr Kaneko has a relationship with Medtronic, Edwards Lifesciences, Abbott, and Baylis Medical.

Dr Tang is a physician proctor for Edwards Lifesciences and Medtronic, as well as a consultant for Abbott, W. L. Gore & Associates, and Medtronic.

Dr Reardon is a consultant for Medtronic, Roston Scientific, and Gove Medical.


The information and views presented on represent the views of the authors and contributors of the material and not of CTSNet. Please review our full disclaimer page here.


I want to congratulate the moderator and the panelist for an excellent presentation on the transcatheter future of mitral valve disease. Nevertheless I feel the title of the presentation is somehow off respect of the final message delivered. The panelists invited have clearly a practice more shifted toward transcatheter then surgical treatment of mitral valve disease and some of the sentences we heard in this video reflect this bias: "You do not need to resect any degenerative mitral valve" (What about SAM?) "Annulus dilatation happen always in a later stage of mitral valve disease" are clearly biased sentences to push and justify procedures (Neochords) that have not still proved any solid data. No mentioned about minimally invasive surgical repair and the importance of long term solid data. Finally the fact that we are pushed by the patients, should not be an excuses to accept moderate results or offer lower long term benefits. The push of industry should not unfocused our responsibility toward patients. For the next panel discussion please invite some surgeons actively involved in minimally invasive and open surgery to have a more vibrant and open minded discussion. Kudo to all of you!

Add comment

Log in or register to post comments